Back

Aberrant oxidative metabolism selects for TET2-deficient hematopoietic stem and progenitor cells

Nino, K. E.; Adema, V.; Gray, A.; Cowan, C. M.; Schleicher, W. E.; Hosseini, M.; Bennett, S. N.; Patel, S. B.; Moreira, S.; Danis, E.; Ma, F.; Lin, H.-Y.; Young, T. N.; Anderson, C. A.; Sharma, D.; Varesi, A.; Filippi, M.-D.; Ito, K.; Dawlaty, M. M.; Huang, G.; Reisz, J. A.; Xie, S. Z.; Chan, S. M.; Tan, L.; Garcia-Manero, G.; Chien, K.; Ganan-Gomez, I.; D'Alessandro, A.; Colla, S.; Pietras, E.

2026-03-02 cancer biology
10.64898/2026.02.28.707294 bioRxiv
Show abstract

The mechanism(s) driving selective expansion of mutant hematopoietic stem and progenitor cells (HSPC) in clonal hematopoiesis (CH) are incompletely understood. Here, we address the role of metabolism in selection for HSPC with loss of function mutations in TET2. Loss of Tet2 in murine HSPC triggers overexpression of glycolysis and oxidative phosphorylation genes and increased oxidative metabolism via an enlarged mitochondrial network. However, Tet2-deficient HSPC maintain a normal redox state. Strikingly, compound loss of the rate-limiting pentose phosphate pathway (PPP) enzyme glucose-6-phosphate dehydrogenase (G6PD) triggers increased reactive oxygen species and impairs the fitness of Tet2-deficient HSPC. We find that aberrant oxidative metabolism is also a feature of HSPC in human CH and clonal cytopenia of unknown significance (CCUS). Overall, our data point to aberrant metabolism as a critical and conserved driver of selection in TET2-deficient CH and identify the PPP as a crucial compensatory pathway needed to maintain their selective advantage. Statement of SignificanceThis study identifies oxidative metabolism as a critical driver of selection for TET2-deficient HSPC in clonal hematopoiesis (CH). It also demonstrates that cellular redox state is a vulnerability that impairs their fitness. These insights establish targetable metabolic pathway(s) that could be exploited in the setting of TET2 mutant CH.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Blood
67 papers in training set
Top 0.1%
14.8%
2
Cell Reports
1338 papers in training set
Top 4%
8.5%
3
Cancer Discovery
61 papers in training set
Top 0.2%
6.9%
4
Nature
575 papers in training set
Top 5%
4.9%
5
Cell Stem Cell
57 papers in training set
Top 0.3%
4.9%
6
Journal of Experimental Medicine
106 papers in training set
Top 0.5%
4.9%
7
eLife
5422 papers in training set
Top 17%
4.9%
8
Developmental Cell
168 papers in training set
Top 4%
4.3%
50% of probability mass above
9
Nature Communications
4913 papers in training set
Top 39%
3.6%
10
Journal of Clinical Investigation
164 papers in training set
Top 1%
3.1%
11
Molecular Cell
308 papers in training set
Top 5%
2.4%
12
Science
429 papers in training set
Top 11%
2.4%
13
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 27%
2.1%
14
Science Advances
1098 papers in training set
Top 12%
2.1%
15
Nature Cell Biology
99 papers in training set
Top 2%
2.1%
16
Cell Metabolism
49 papers in training set
Top 0.9%
1.9%
17
Blood Advances
54 papers in training set
Top 0.7%
1.7%
18
Nature Cancer
35 papers in training set
Top 0.7%
1.7%
19
EMBO Molecular Medicine
85 papers in training set
Top 2%
1.5%
20
Nature Genetics
240 papers in training set
Top 5%
1.3%
21
Cell
370 papers in training set
Top 13%
1.3%
22
Leukemia
39 papers in training set
Top 0.6%
1.2%
23
Science Translational Medicine
111 papers in training set
Top 5%
0.9%
24
Immunity
58 papers in training set
Top 4%
0.9%
25
JCI Insight
241 papers in training set
Top 6%
0.8%
26
Cell Genomics
162 papers in training set
Top 6%
0.8%
27
Haematologica
24 papers in training set
Top 0.4%
0.8%
28
PLOS Genetics
756 papers in training set
Top 15%
0.8%
29
Cancer Research
116 papers in training set
Top 3%
0.8%
30
Genes & Development
90 papers in training set
Top 1%
0.8%